Impact of direct‐acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta‐analysis

2021 ◽  
Vol 28 (5) ◽  
pp. 739-754
Author(s):  
Yeva Sahakyan ◽  
Victoria Lee‐Kim ◽  
Karen E. Bremner ◽  
Joanna M. Bielecki ◽  
Murray D. Krahn
Keyword(s):  
Systematic Review ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Meta Analysis ◽  
Mortality And Morbidity ◽  
Direct Acting Antiviral ◽  
Direct Acting

Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review

2018 ◽  
Vol 13 (5) ◽  
pp. 775-790 ◽  
Author(s):  
Eleonora Tamborini Permunian ◽  
Lorenzo Gervaso ◽  
Victor Gerdes ◽  
Lorenzo Moja ◽  
Luigina Guasti ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Drugs ◽  
Vascular Events ◽  
Direct Acting Antiviral ◽  
Direct Acting

Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients

2020 ◽  
Vol 16 (11) ◽  
pp. 675-686
Author(s):  
Longteng Ma ◽  
Jiluo Liu ◽  
Wei Wang ◽  
Fan Yang ◽  
Ping Li ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Meta Analysis ◽  
Antiviral Treatment ◽  
Direct Acting Antiviral ◽  
Study Results ◽  
Direct Acting ◽  
Better Than

Aim: It was controversial whether direct-acting antiviral (DAA) is better than interferon-based therapy (IBT) in preventing HCV-related hepatocellular carcinoma (HCC). Therefore, we accomplished this large, stepwise meta-analysis. Materials & methods: The PubMed, Cochrane and ScienceDirect were searched for studies published during January 2009–March 2019. Antiviral type, number of chronic hepatitis C (CHC) patients, number of HCC cases from CHC patients, sustained virological response (SVR) status and important covariate data were extracted from each study. Results & conclusion: It is demonstrated that antiviral treatment reduces the occurrence of HCC in patients with CHC; achieving SVR to antiviral treatment reduces HCC; DAA treatment is not better than IBT in the prophylaxis of HCC; DAA treatment and cirrhosis are independently associated with a higher incidence of HCC than IBT in middle-aged CHC patients who achieve SVR.

Effectiveness of direct‐acting agents for chronic hepatitis C treatment in South America: A systematic review and meta‐analysis

2020 ◽  
Vol 27 (12) ◽  
pp. 1396-1407
Author(s):  
Elio C. Castro Filho ◽  
Juliana Piedade ◽  
Rodolfo Castro ◽  
Paula M. Luz ◽  
Flavia Fernandes ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
South America ◽  
Chronic Hepatitis C ◽  
Meta Analysis ◽  
Hepatitis C Treatment ◽  
Direct Acting

scholarly journals High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Zuqiang Fu ◽  
Chen Dong ◽  
Zhijun Ge ◽  
Chunhui Wang ◽  
Yun Zhang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Meta Analysis ◽  
Sustained Virological Response Rate ◽  
Random Effects Models ◽  
Direct Acting Antiviral ◽  
Drug Intolerance ◽  
Arcsine Transformation ◽  
Direct Acting

Direct-acting antiviral (DAA) treatment for 8 weeks has a sustained virological response rate in adults with chronic hepatitis C. We have conducted a systematic review and meta-analysis to compare the efficacy and safety of the 8-week vs. 12/24-week DAA treatment in adolescents and children with CHC. The PubMed, Web of Science, and Cochrane databases were searched for the relevant articles from January 1, 2017 to August 28, 2020 and further screened for literature reviews on April 1, 2021. Pool proportions with 95% CIs for SVR12 were summarized with fixed/random effects models using Freeman–Tukey double arcsine transformation. Subgroup analysis was used to explore the source of heterogeneity. Thirty-six relevant publications were identified. For adolescents aged 12–17 years old, the pooled SVR12 and AE rate were 99.4% (95% CI: 98.7–99.9) and 34.7% (95% CI: 31.9–37.6). No one discontinued treatment due to drug intolerance. In addition, the SVR12 adolescents treated for 12 and 8/24 weeks were 99.3% (95% CI: 98.4–99.9) and 100%, respectively. The pooled SVR12 rate, AEs, and SAEs for children younger than 12 years were 98.9% (95% CI: 97.3–99.8), 51.6% (95% CI: 47.0–56.2), and 1.1% (95% CI: 0.4–2.5), respectively. The most common AE was fatigue (28.4%). The SVR12 was 98.8% (95% CI: 97.1–99.8) and 100% for the pediatric patients treated for 12 weeks and 8/24 weeks, respectively. Taken together, DAAs are generally effective against CHC and well-tolerated by the adolescents and children. A treatment duration of 8 weeks is equally effective and safe as 12/24 weeks in this demographic group.

Sign in / Sign up

Export Citation Format

Share Document